News

Investors' Class Action Opportunity Against Easterly ROCMuni Fund

Investors' Class Action Opportunity Against Easterly ROCMuni Fund

Opportunities for Investors in the Easterly ROCMuni Fund

The Schall Law Firm has recently informed investors about their option to file a class action lawsuit against the Easterly ROCMuni High Income Municipal Bond Fund (ticker RMJAX). Investigations have raised concerns about the Fund’s compliance with federal securities laws.

If you are someone who invested in the Fund's securities during the period of May 5, 2023, to June 12, 2025, you may be eligible to participate in this legal pursuit for justice. The lawsuit aims to address various misleading statements made by the Fund concerning its portfolio valuations and overall performance.

Understanding the Allegations Against the Fund

According to the recent complaint, it is alleged that the Easterly ROCMuni Fund conducted itself in a misleading manner by reporting inflated asset values. These inflated valuations gave investors a false sense of the stability and performance of their investments. Moreover, even though the Fund claimed to manage a diverse array of assets, it was heavily invested in illiquid securities, raising serious questions about its valuation methods.

This overstatement of the net asset value (NAV) and its reported performance led to significant damages for investors once the truth began to surface in the market. As the status of these issues gained traction, investors became more aware of the substantial discrepancies between reported values and the actual market situation.

Actions Available for Affected Investors

Investors affected by this situation are encouraged to connect with the Schall Law Firm for further assistance in understanding their potential claims. It is crucial for individuals who have suffered losses to reach out before the deadline for filing claims. Currently, the class action has yet to receive formal certification, leaving investors at a crossroads concerning their next steps.

Those who believe they may be eligible to join this lawsuit should consider contacting the firm to assess their rights. It’s a significant opportunity for investors to hold the Fund accountable for the allegations of misconduct.

The Role of the Schall Law Firm

The Schall Law Firm, recognized for its expertise in securities class action lawsuits, represents a global clientele of investors seeking justice in matters like these. Their mission is to uphold the rights of shareholders and ensure every investor can seek recourse for financial damages incurred from negligent or deceptive practices.

Investors can rest assured that contacting the firm for guidance is free of charge. Representatives at the Firm are prepared to discuss the particulars of your situation and explore possible legal avenues to recover your losses.

Frequently Asked Questions

What is the Easterly ROCMuni Fund lawsuit about?

The lawsuit addresses allegations of securities fraud against the Easterly ROCMuni High Income Municipal Bond Fund due to misleading statements and inflated asset valuations.

Who can join the class action against the Easterly ROCMuni Fund?

Any investor who purchased the Fund's securities between May 5, 2023, and June 12, 2025, may be eligible to join the class action.

How can I participate in the lawsuit?

Affected investors should contact the Schall Law Firm before the participation deadline to learn more about their eligibility and the claims process.

What is the deadline for joining the class action?

The deadline for participating in the class action lawsuit is September 22, 2025.

Is there a cost involved in contacting the Schall Law Firm?

No, consulting with the Schall Law Firm is free, allowing investors to understand their rights without financial obligations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 170

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 211

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 268

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 227

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 234

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 84

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 186

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 193

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Updates for Edwards Lifesciences Corporation Investors

Updated Category News Views 157

Important Updates for Edwards Lifesciences Corporation Investors New York - Investors of Edwards Lifesciences Corporation (NYSE: EW) should remain aware of the recent developments concerning the securities class action lawsuit that affects their investments. This information is crucial for anyone who purchased securities of Edwards Lifesciences within the specified class...

Continue Reading
Investors Urged to Act: Zenas BioPharma Class Action Notice

Updated Category News Views 147

Investors Encouraged to Participate in Zenas BioPharma Class Action The Gross Law Firm has issued an important notice for shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO), urging those who have incurred financial losses to seek options regarding a pending class action. This notice highlights the importance of taking timely steps for potential recovery. Understanding...

Continue Reading
Zinzino's Strategic Merger with It Works! Enhances Growth Potential

Updated Category News Views 1021

Zinzino and It Works! Merger: A Game-Changer in Health Sales Zinzino AB has officially announced a remarkable merger with the US-based direct sales company It Works!, a bold and strategic decision that is set to enhance the distribution capabilities of both companies across various markets. This merger, which combines unique strengths and resources, opens new avenues for...

Continue Reading
NEXE Innovations Expands Compostable Product Line in North America

Updated Category News Views 164

Exciting Developments at NEXE Innovations Based in Windsor, Ontario, NEXE Innovations Inc. is making significant strides in the compostable materials industry. Recently, the company announced a pivotal delivery of over 80,000 compostable coffee pods, available in three new product SKUs, to an esteemed office coffee services distributor in North America. Expanding Product...

Continue Reading
SubSplit Acquires Ideal Consolidated: Legacy Meets Future

Updated Category News Views 236

Market moves may come and go, but the real power play is knowing when a strategic acquisition is worth its weight in gold. SubSplit Services Group just pulled off one such move by nabbing Ideal Consolidated, Inc., a company that's been a fixture in South Bend, Indiana, since 1956. Yeah, that's a lot of history, folks, and SubSplit's decision to add that to their portfolio...

Continue Reading